AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23144450 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase treatment
Number of subjects: 149
Study 21448308 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (2 x 100 mg) and tramadol (4 x 100 mg)
Number of subjects: 40
Study 21448308 — intervention group
Group type: COMPARATOR
Intervention: Control group received tramadol (4 x 100 mg)
Number of subjects: 40
Study 19257824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (IBN) 2 mg intravenously every 3 months
Number of subjects: 35
Study 19257824 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CTR)
Number of subjects: 35
Study 19257824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (IBN)
Number of subjects: 35
Study 16959931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, home-based case management intervention
Number of subjects: 147
Study 16959931 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 147
Study 16015459 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (AT) for 10 weeks, with weekly sessions and daily practice at home
Number of subjects: 22
Study 16015459 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study 12581053 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost intervention in conservative treatment
Number of subjects: 2
Study 12581053 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative treatment
Number of subjects: 2
Study 9924166 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency revascularization (via percutaneous transluminal coronary angioplasty or coronary artery bypass grafting)
Number of subjects: 0
Study 9924166 — intervention group
Group type: COMPARATOR
Intervention: Initial medical stabilization
Number of subjects: 0
Study 9924166 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency revascularization
Number of subjects: 0
Study 7558772 — intervention group
Group type: EXPERIMENTAL
Intervention: Associate learning subtest from the Wechsler Memory Scale
Number of subjects: 0
Study 7558772 — intervention group
Group type: EXPERIMENTAL
Intervention: Benton's Visual Retention test
Number of subjects: 0
Study 7558772 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Word Association Task (FAS)
Number of subjects: 0
Study 2374076 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal-plus
Number of subjects: 42
Study 2374076 — intervention group
Group type: COMPARATOR
Intervention: Traditional
Number of subjects: 42
Study 2374076 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 42
Study 7294327 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine 2 mg
Number of subjects: 32
Study 7294327 — intervention group
Group type: COMPARATOR
Intervention: Control (no physostigmine)
Number of subjects: 32
Study 31386821 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT), performed three days per week for four weeks, consisting of cycling bouts of 30 s each at 80% MAP, followed by four minutes of recovery at 40% MAP.
Number of subjects: 17
Study 31386821 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 17
Study 31386821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups performed a graded exercise test (GXT) before and after the intervention.
Number of subjects: 17
Study 31386821 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 17
Study 29486960 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (20Hz)
Number of subjects: 27
Study 29486960 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 27
Study 28455597 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis treatment
Number of subjects: 27673
Study 25533872 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 19
Study 25533872 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 21561791 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous androgen deprivation therapy (CAD)
Number of subjects: 193
Study 21561791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation therapy (IAD)
Number of subjects: 193
Study 20948238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 4 mg/day for ≥30 months
Number of subjects: 33
Study 20948238 — intervention group
Group type: COMPARATOR
Intervention: Control group (tocopherol nicotinate 300 mg/day, helenien 15 mg/day, or no medication) for ≥30 months
Number of subjects: 33
Study 20948238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 4 mg/day for total observational period
Number of subjects: 33
Study 20948238 — intervention group
Group type: COMPARATOR
Intervention: Control group for total observational period
Number of subjects: 33
Study 18329587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 0
Study 18329587 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0
Study 18329587 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 0
Study 18329587 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 18329587 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0
Study 16458337 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole prophylaxis (sulphamethoxazole 800 mg/trimethoprim 160 mg daily)
Number of subjects: 533
Study 14690096 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 7 microg kg(‐1)
Number of subjects: 17
Study 14690096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 10617532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracker trials
Number of subjects: 0
Study 8639444 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) 0.3 microgram/kg infused over 30 min
Number of subjects: 8
Study 8639444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1451052 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 5‐fluorouracil (1000 mg/m2 for 48 hours)
Number of subjects: 16
Study 1451052 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of 5‐fluorouracil (500 mg/m2 x 2 in 48 hours)
Number of subjects: 16
Study 1451052 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 5‐fluorouracil
Number of subjects: 16
Study 1451052 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of 5‐fluorouracil
Number of subjects: 16
Study 6148843 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-directed prolonged exposure in vivo (PE)
Number of subjects: 42
Study 6148843 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamically oriented supportive therapy (ST)
Number of subjects: 42
Study 6148843 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy (R)
Number of subjects: 42
Study 6148843 — intervention group
Group type: COMPARATOR
Intervention: Basal therapy (B)
Number of subjects: 42
Study 29017811 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer feedback
Number of subjects: 79
Study 29017811 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple stakeholders separately
Number of subjects: 79
Study 29017811 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple stakeholders combined
Number of subjects: 79
Study 29952519 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-degree head-up tilt position
Number of subjects: 44
Study 29952519 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position
Number of subjects: 44
Study 25192478 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-4 group (valve initially set to 20 cm H₂O and gradually reduced to 4 cm H₂O)
Number of subjects: 68
Study 25192478 — intervention group
Group type: COMPARATOR
Intervention: 12 group (valve kept at a medium pressure setting of 12 cm H₂O)
Number of subjects: 68
Study 22706940 — intervention group
Group type: EXPERIMENTAL
Intervention: FLIRT (First Line Intermittent Recompression Technique)
Number of subjects: 29
Study 22706940 — intervention group
Group type: COMPARATOR
Intervention: Control (Buehlmann‐based decompression profile)
Number of subjects: 29
Study 22706940 — intervention group
Group type: EXPERIMENTAL
Intervention: FLIRT
Number of subjects: 29
Study 22706940 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study 19896325 — intervention group
Group type: EXPERIMENTAL
Intervention: Photon stimulation
Number of subjects: 121
Study 19896325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 17966969 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M, n = 13)
Number of subjects: 26
Study 17966969 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide (G, n = 13)
Number of subjects: 26
Study 16310013 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 0
Study 12761365 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-protein, high-fat diet
Number of subjects: 63
Study 12383809 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-doubling technology glaucoma screening protocol (FDT-GSP)
Number of subjects: 14817
Study 10402259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense but task-irrelevant 'accessory' stimulus accompanying the imperative stimulus in a choice reaction task
Number of subjects: 0
Study 10402259 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition with three alternative responses
Number of subjects: 0
Study 10402259 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel dependent measure introduced: latency of spontaneous, post-trial blinking
Number of subjects: 0
Study 7480274 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 6 mg IM preoperatively
Number of subjects: 50
Study 7480274 — intervention group
Group type: COMPARATOR
Intervention: No steroid treatment
Number of subjects: 50
Study 2381618 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% terconazole cream
Number of subjects: 0
Study 2381618 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6% terconazole cream
Number of subjects: 0
Study 2381618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7030835 — intervention group
Group type: EXPERIMENTAL
Intervention: CDCA (12‐15 mg/kg/day)
Number of subjects: 116
Study 7030835 — intervention group
Group type: COMPARATOR
Intervention: UDCA (5‐6 mg/kg/day)
Number of subjects: 116
Study 7030835 — intervention group
Group type: COMPARATOR
Intervention: UDCA (10‐12 mg/kg/day)
Number of subjects: 116
Study 31888729 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 120
Study 31888729 — intervention group
Group type: COMPARATOR
Intervention: One-anastomosis gastric bypass (OAGB)
Number of subjects: 120
Study 28342637 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus short-term prednisone (1000 mg IV on days 0 and 14, 500 mg at months 12 and 18; prednisone 0.5 or 1.0 mg/kg per day tapered over 3 or 6 months)
Number of subjects: 90
Study 28342637 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone (1.0 or 1.5 mg/kg per day tapered over 12 or 18 months)
Number of subjects: 90
Study 28342637 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 90
Study 28342637 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus short-term prednisone
Number of subjects: 90
Study 26073163 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA)
Number of subjects: 175
Study 26073163 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 175
Study 23374963 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracodorsal nerve divided during reconstruction (group 1)
Number of subjects: 29
Study 23374963 — intervention group
Group type: COMPARATOR
Intervention: Thoracodorsal nerve preserved during reconstruction (group 2)
Number of subjects: 29
Study 21601366 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 100
Study 21601366 — intervention group
Group type: COMPARATOR
Intervention: Baseline conditions
Number of subjects: 100
Study 21601366 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone suppression test (DST)
Number of subjects: 100
Study 21601366 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-potentiated startle (FPS)
Number of subjects: 100
Study 19119169 — intervention group
Group type: EXPERIMENTAL
Intervention: Refrigerant (1,1,1,3,3‐pentafluoropropane/1,1,1,2‐tetrafluoroethane) applied for 5 seconds
Number of subjects: 16
Study 19119169 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthetic gel (20 percent benzocaine gel) applied for 2 minutes
Number of subjects: 16
Study 17483861 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with ILM peeling
Number of subjects: 11
Study 15155717 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHO solution before and during training and 20% solution post-exercise (H-CHO trial)
Number of subjects: 6
Study 15155717 — intervention group
Group type: COMPARATOR
Intervention: 2% CHO solution before and during training and 2% solution post-exercise (L-CHO trial)
Number of subjects: 6
Study 15155717 — intervention group
Group type: EXPERIMENTAL
Intervention: H-CHO trial
Number of subjects: 6
Study 15155717 — intervention group
Group type: COMPARATOR
Intervention: L-CHO trial
Number of subjects: 6
Study 11439734 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (5 to 50 mg)
Number of subjects: 672
Study 11439734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study 9603669 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied 1% beta‐LHA formulation
Number of subjects: 0
Study 9603669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7522547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 100
Study 7522547 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 100
Study 3403064 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (180 mg/week)
Number of subjects: 0
Study 3403064 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (180 mg/week) plus vitamin A (100,000 IU/week)
Number of subjects: 0
Study 3403064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31663369 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative progressive resistance training (PRT) for 4 weeks followed by postoperative PRT for 4 weeks
Number of subjects: 59
Study 31663369 — intervention group
Group type: COMPARATOR
Intervention: Control group (lived as usual for 4 weeks before TKA, followed by 4 weeks postoperative PRT)
Number of subjects: 59
Study 31663369 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative progressive resistance training (PRT)
Number of subjects: 59
Study 31663369 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 29402370 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive underfeeding
Number of subjects: 82
Study 29402370 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral feeding
Number of subjects: 82
Study 26613819 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg misoprostol with 10 units of oxytocin
Number of subjects: 288
Study 26613819 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 10 units of oxytocin
Number of subjects: 288
Study 24914476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 20
Study 22512515 — intervention group
Group type: EXPERIMENTAL
Intervention: Provox Vega
Number of subjects: 31
Study 22512515 — intervention group
Group type: COMPARATOR
Intervention: Blom-Singer Classic Indwelling
Number of subjects: 31
Study 20547039 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 54
Study 20547039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 20547039 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 54
Study 18452345 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg/day
Number of subjects: 694
Study 18452345 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/day
Number of subjects: 694
Study 18452345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 694
Study 16167707 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (60 mg tablet containing 300 microg ferrous sulphate and 400 microg folic acid for three months)
Number of subjects: 207
Study 16167707 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (60 mg tablet containing 300 microg ferrous sulphate and 400 microg folic acid for three months)
Number of subjects: 207
Study 16167707 — intervention group
Group type: COMPARATOR
Intervention: Control group (not supplemented)
Number of subjects: 207
Study 15083762 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask (NM)
Number of subjects: 16
Study 15083762 — intervention group
Group type: COMPARATOR
Intervention: Full face mask (FFM)
Number of subjects: 16
Study 11039133 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural surfactant
Number of subjects: 24
Study 11039133 — intervention group
Group type: COMPARATOR
Intervention: Synthetic surfactant
Number of subjects: 24
Study 9372401 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training course
Number of subjects: 151
Study 9372401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training course)
Number of subjects: 151
Study 1590012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossiplex retard
Number of subjects: 12
Study 1590012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono-Tridin
Number of subjects: 12
Study 1590012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossin
Number of subjects: 12
Study 2863185 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide
Number of subjects: 30
Study 2863185 — intervention group
Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 30
Study 3219882 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg pinaverium bromide intravenously
Number of subjects: 30
Study 3219882 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg pinaverium bromide intravenously
Number of subjects: 30
Study 3219882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31933461 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based water intervention
Number of subjects: 0
Study 31933461 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to intervention uptake
Number of subjects: 0
Study 31933461 — intervention group
Group type: EXPERIMENTAL
Intervention: Enablers to intervention uptake
Number of subjects: 0
Study 31933461 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to health reporting
Number of subjects: 0
Study 31933461 — intervention group
Group type: EXPERIMENTAL
Intervention: Enablers to health reporting
Number of subjects: 0
Study 30849015 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Dentin Sealing (IDS) with PermaCem Dual Smartmix (PER) and tribochemical silica coating (TBC)
Number of subjects: 60
Study 30849015 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Dentin Sealing (IDS) with Panavia F2.0 (PAN) and tribochemical silica coating (TBC)
Number of subjects: 60
Study 30849015 — intervention group
Group type: COMPARATOR
Intervention: Delayed Dentin Sealing (DDS) with PermaCem Dual Smartmix (PER) and airborne particle abrasion (APA)
Number of subjects: 60
Study 30849015 — intervention group
Group type: COMPARATOR
Intervention: Delayed Dentin Sealing (DDS) with Panavia F2.0 (PAN) and airborne particle abrasion (APA)
Number of subjects: 60
Study 28613996 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater personal resilience resources (composite variable of self-esteem, mastery, and optimism)
Number of subjects: 254
Study 28613996 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater personal resilience resources
Number of subjects: 254
Study 25640830 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSPER intervention
Number of subjects: 28
Study 25640830 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal involvement
Number of subjects: 28
Study 25640830 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD4 variation
Number of subjects: 28
Study 25640830 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin transporter linked polymorphic region (5-HTTLPR)
Number of subjects: 28
Study 23775505 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at steady-state effect-site concentrations of 0, 1.2, 1.8, 2.4, 3, 3.6, 4.8, and 6 ng/ml
Number of subjects: 16
Study 23775505 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of three surrogate parameters (pupil diameter, light reflex amplitude, and tracking performance)
Number of subjects: 16
Study 21569011 — intervention group
Group type: EXPERIMENTAL
Intervention: Context therapy
Number of subjects: 0
Study 19505910 — intervention group
Group type: COMPARATOR
Intervention: HPV-16 infection
Number of subjects: 0
Study 19505910 — intervention group
Group type: COMPARATOR
Intervention: HPV-6 or -11
Number of subjects: 0
Study 19505910 — intervention group
Group type: COMPARATOR
Intervention: HPV-16
Number of subjects: 0
Study 16800900 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy plus chemotherapy
Number of subjects: 0
Study 16800900 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain radiotherapy
Number of subjects: 0
Study 16800900 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 0
Study 11919130 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x NPH daily
Number of subjects: 104
Study 11919130 — intervention group
Group type: COMPARATOR
Intervention: 1 x NPH
Number of subjects: 104
Study 10503820 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term acid inhibition therapy
Number of subjects: 0
Study 10503820 — intervention group
Group type: COMPARATOR
Intervention: Long-term acid-inhibitory therapy for an average of three years
Number of subjects: 0
Study 10503820 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term acid inhibition in individuals with H. pylori infection
Number of subjects: 0
Study 7751706 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone
Number of subjects: 0
Study 7751706 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 0